HUP0500616A3 - Processes for preparing calcium salt forms of statins - Google Patents
Processes for preparing calcium salt forms of statinsInfo
- Publication number
- HUP0500616A3 HUP0500616A3 HU0500616A HUP0500616A HUP0500616A3 HU P0500616 A3 HUP0500616 A3 HU P0500616A3 HU 0500616 A HU0500616 A HU 0500616A HU P0500616 A HUP0500616 A HU P0500616A HU P0500616 A3 HUP0500616 A3 HU P0500616A3
- Authority
- HU
- Hungary
- Prior art keywords
- statins
- processes
- calcium salt
- salt forms
- preparing calcium
- Prior art date
Links
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 title 1
- 159000000007 calcium salts Chemical group 0.000 title 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/55—Acids; Esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D215/14—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/30—Oxygen atoms, e.g. delta-lactones
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyrane Compounds (AREA)
- Quinoline Compounds (AREA)
- Pyridine Compounds (AREA)
- Pyrrole Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31281201P | 2001-08-16 | 2001-08-16 | |
| US10/037,412 US6528661B2 (en) | 2000-11-16 | 2001-10-24 | Hydrolysis of [R(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino) carbonyl]-1H-pyrrole-1-heptanoic acid esters with calcium hydroxide |
| PCT/US2002/026012 WO2003016317A1 (en) | 2001-08-16 | 2002-08-16 | Processes for preparing calcium salt forms of statins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0500616A2 HUP0500616A2 (hu) | 2005-11-28 |
| HUP0500616A3 true HUP0500616A3 (en) | 2011-07-28 |
Family
ID=26714105
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0500616A HUP0500616A3 (en) | 2001-08-16 | 2002-08-16 | Processes for preparing calcium salt forms of statins |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP1425287A4 (hu) |
| JP (2) | JP4188826B2 (hu) |
| CN (1) | CN100430405C (hu) |
| AU (1) | AU2002324715B2 (hu) |
| CA (1) | CA2450820C (hu) |
| CZ (1) | CZ2004337A3 (hu) |
| HR (1) | HRPK20040255B3 (hu) |
| HU (1) | HUP0500616A3 (hu) |
| IL (2) | IL160077A0 (hu) |
| IS (1) | IS7148A (hu) |
| MX (1) | MXPA04001451A (hu) |
| NO (1) | NO20041082L (hu) |
| NZ (1) | NZ529913A (hu) |
| PL (1) | PL370407A1 (hu) |
| SK (1) | SK1402004A3 (hu) |
| TR (1) | TR200302281T2 (hu) |
| WO (1) | WO2003016317A1 (hu) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7411075B1 (en) | 2000-11-16 | 2008-08-12 | Teva Pharmaceutical Industries Ltd. | Polymorphic form of atorvastatin calcium |
| NZ526022A (en) * | 2000-11-16 | 2005-04-29 | Teva Pharma | Hydrolysis of [R(R*,R )]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid esters with calcium hydroxide |
| US7501450B2 (en) | 2000-11-30 | 2009-03-10 | Teva Pharaceutical Industries Ltd. | Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
| IL156055A0 (en) | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
| WO2002057229A1 (en) | 2001-01-19 | 2002-07-25 | Biocon India Limited | FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN) |
| US7361772B2 (en) | 2001-08-16 | 2008-04-22 | Biocon Limited | Process for the production of atorvastatin calcium |
| CA2412012C (en) | 2001-11-20 | 2011-08-02 | Ed. Geistlich Soehne Ag Fuer Chemische Industrie | Resorbable extracellular matrix containing collagen i and collagen ii for reconstruction of cartilage |
| BR0215644A (pt) | 2002-03-18 | 2004-12-21 | Biocon Ltd | Inibidores de redutase de hmg-coa amorfos do tamanho de partìcula desejado |
| EP1585736A2 (en) * | 2002-05-21 | 2005-10-19 | Ranbaxy Laboratories, Ltd. | Process for the preparation of rosuvastatin |
| US7179942B2 (en) | 2002-07-05 | 2007-02-20 | Bicon Limited | Halo-substituted active methylene compounds |
| GB0218781D0 (en) * | 2002-08-13 | 2002-09-18 | Astrazeneca Ab | Chemical process |
| CA2513837A1 (en) * | 2003-02-12 | 2004-08-26 | Paul Adriaan Van Der Schaaf | Crystalline forms of pitavastatin calcium |
| SI1631533T1 (sl) | 2003-04-22 | 2009-08-31 | Bicon Ltd | Nov postopek za stereoselektivno redukcijo beta - ketoestrov |
| GB0312896D0 (en) | 2003-06-05 | 2003-07-09 | Astrazeneca Ab | Chemical process |
| BRPI0412786A (pt) * | 2003-07-25 | 2006-09-26 | Avecia Pharmaceuticals Ltd | processo para a preparação de um composto, e, composto |
| AU2003269477A1 (en) * | 2003-08-26 | 2005-03-10 | Biocon Limited | Novel process for preparation of 7-(3-(4-fluorophenyl)-1-(1-methylethyl)-1h-indol-2-yl)-3, 5-dihydroxy-6-heptenoic acid sodium salt |
| EP1816126A1 (en) * | 2003-08-28 | 2007-08-08 | Teva Pharmaceutical Industries Limited | Process for preparation of rosuvastatin calcium |
| WO2005023778A2 (en) * | 2003-08-28 | 2005-03-17 | Teva Pharmaceutical Industries Ltd. | Process for preparation of rosuvastatin calcium |
| UY28501A1 (es) | 2003-09-10 | 2005-04-29 | Astrazeneca Uk Ltd | Compuestos químicos |
| WO2005026107A1 (en) | 2003-09-18 | 2005-03-24 | Biocon Limited | Novel process for the preparation of tert-butyl 6-cyano-5-hydroxy-3-oxohexanoate |
| EP1678148A1 (en) * | 2003-10-22 | 2006-07-12 | Ranbaxy Laboratories Limited | Process for the preparation of amorphous rosuvastatin calcium |
| GB0324791D0 (en) * | 2003-10-24 | 2003-11-26 | Astrazeneca Ab | Chemical process |
| TW200526596A (en) | 2003-11-24 | 2005-08-16 | Teva Pharma | Crystalline ammonium salts of rosuvastatin |
| MY147202A (en) * | 2003-11-26 | 2012-11-14 | Novartis Ag | Compositions comprising organic compounds |
| CA2546894C (en) | 2003-12-02 | 2009-09-08 | Teva Pharmaceutical Industries Ltd. | Reference standard for characterization of rosuvastatin |
| TWI328006B (en) * | 2003-12-26 | 2010-08-01 | Nissan Chemical Ind Ltd | Crystal form of quinoline compound and process for its production |
| EP1711489B1 (en) * | 2003-12-29 | 2012-12-26 | LEK Pharmaceuticals d.d. | Process for preparing amorphous (4r-cis)-6-[2-[3-phenyl-4-(phenylcarbamoyl)-2-(4-fluorophenyl)-5-(1-methyl)-pyrrol-1-yl]-2,2-dimethyl-[1,3]-dioxane-4-yl-acetic acid |
| CZ200486A3 (cs) * | 2004-01-16 | 2005-08-17 | Zentiva, A.S. | Způsob výroby hemivápenaté soli (E)-7-[4-(4-fluorfenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxy-6-heptenové kyseliny |
| EP1737828A1 (en) * | 2004-01-19 | 2007-01-03 | Ranbaxy Laboratories Limited | Amorphous magnesium salts of rosuvastatin |
| SI21745A (sl) * | 2004-04-09 | 2005-10-31 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Polimorfi derivata 1-pirol-1-heptanojske kisline, intermediata za pripravo atorvastatina |
| JP2007508379A (ja) | 2004-07-13 | 2007-04-05 | テバ ファーマシューティカル インダストリーズ リミティド | Ｔｅｍｐｏ媒介型酸化段階を包含するロスバスタチンの調製方法 |
| BRPI0514189A (pt) * | 2004-08-06 | 2008-06-03 | Transform Pharmaceuticals Inc | composições farmacêuticas de estatina e métodos de tratamento relacionados |
| TWI353981B (en) | 2005-02-22 | 2011-12-11 | Teva Pharma | Preparation of rosuvastatin |
| CZ299215B6 (cs) * | 2005-06-29 | 2008-05-21 | Zentiva, A. S. | Zpusob výroby hemivápenaté soli (E)-7-[4-(4-fluorofenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl] (3R,5S)-3,5-dihydroxy-6-heptenovékyseliny |
| RU2008108078A (ru) * | 2005-08-04 | 2009-09-10 | Трансформ Фармасьютикалз, Инк. (Us) | Новые препаративные формы, включающие фенофибрат и статин, и соответствующие способы лечения |
| JP2008515931A (ja) | 2005-08-16 | 2008-05-15 | テバ ファーマシューティカル インダストリーズ リミティド | 結晶形ロスバスタチン中間体 |
| CN100371709C (zh) * | 2005-12-12 | 2008-02-27 | 重庆医药工业研究院有限责任公司 | 一种用液相色谱法分离测定匹伐他汀及其光学异构体的方法 |
| WO2007125547A2 (en) * | 2006-05-03 | 2007-11-08 | Manne Satyanarayana Reddy | Novel process for statins and its pharmaceutically acceptable salts thereof |
| US8404841B2 (en) | 2006-10-09 | 2013-03-26 | Msn Laboratories Limited | Process for the preparation of statins and their pharmaceutically acceptable salts thereof |
| EP2022784A1 (en) | 2007-08-08 | 2009-02-11 | LEK Pharmaceuticals D.D. | Process for the preparation of methyl ester of rosuvastatin |
| WO2010089770A2 (en) | 2009-01-19 | 2010-08-12 | Msn Laboratories Limited | Improved process for the preparation of highly pure (3r,5s)-7-[2-cyclopropyl-4-(4-fluorophenyl) quinolin-3-yl]-3,5-dihydroxy-6(e)-heptenoic acid and pharmaceutically acceptable salts thereof |
| EP2526099B1 (en) | 2010-01-18 | 2016-03-30 | MSN Laboratories Limited | Improved process for the preparation of amide intermediates and their use thereof |
| HUP1000299A2 (hu) | 2010-06-08 | 2012-02-28 | Nanoform Cardiovascular Therapeutics Ltd | Nanostrukturált Atorvastatint, gyógyszerészetileg elfogadott sóit és kokristályait tartalmazó készítmény és eljárás elõállításukra |
| EP3178812A1 (en) * | 2010-11-12 | 2017-06-14 | Hetero Research Foundation | Novel polymorphs of pitavastatin calcium |
| HU229260B1 (en) * | 2010-11-29 | 2013-10-28 | Egis Gyogyszergyar Nyrt | Process for preparation of rosuvastatin salts |
| CN102875504A (zh) * | 2011-07-13 | 2013-01-16 | 华南理工大学 | 4,5,6,7-四氢普伐他汀及其盐在心血管上的用途 |
| CN102302452B (zh) * | 2011-09-14 | 2012-11-21 | 海南美大制药有限公司 | 匹伐他汀钙脂质体固体制剂 |
| CN102796036B (zh) * | 2012-09-12 | 2014-06-04 | 江苏阿尔法药业有限公司 | 一种阿托伐他汀钙的制备方法 |
| CN103724278B (zh) * | 2013-12-12 | 2019-03-29 | 江苏阿尔法药业有限公司 | 他汀类中间体及其衍生物的制备方法 |
| CN106029895B (zh) * | 2014-02-06 | 2021-07-16 | 株式会社Api | 瑞舒伐他汀钙及其中间体的生产方法 |
| KR20160126700A (ko) | 2015-04-24 | 2016-11-02 | 미래파인켐 주식회사 | 스타틴의 중간체, 이의 제조방법 및 이를 이용한 로수바스타틴의 제조방법 |
| CN105111173B (zh) * | 2015-06-26 | 2017-06-23 | 上海应用技术学院 | 他汀含氟衍生物及其用途 |
| CN105017231B (zh) * | 2015-06-26 | 2018-01-26 | 上海应用技术学院 | 多取代吲哚类他汀含氟修饰物及其用途 |
| CN113620871A (zh) | 2015-08-05 | 2021-11-09 | 株式会社Api | 生产匹伐他汀钙的方法 |
| CN111362856B (zh) * | 2020-04-29 | 2023-08-18 | 福建海西新药创制股份有限公司 | 一种利用微反应装置生产阿托伐他汀钙的方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5817443B2 (ja) * | 1976-11-02 | 1983-04-07 | 三共株式会社 | Ｍｌ−２３６ｂ金属塩を主成分とする高脂血症治療剤 |
| US4137322A (en) * | 1976-11-02 | 1979-01-30 | Sankyo Company Limited | ML-236B carboxylic acid derivatives and their use as antihyperlipemic agents |
| US4857547A (en) * | 1988-01-07 | 1989-08-15 | Merck & Co., Inc. | Novel HMG-CoA reductase inhibitors |
| PL193479B1 (pl) * | 1995-07-17 | 2007-02-28 | Warner Lambert Co | Formy krystaliczne hydratu atorwastatyny, kompozycja farmaceutyczna zawierająca formę krystaliczną I hydratu atorwastatyny oraz jej zastosowanie |
| US5669156A (en) * | 1996-08-28 | 1997-09-23 | Fleetwood Systems, Inc. | Can end curing system with magnetic fanning and belt conveying |
| NZ503982A (en) * | 1997-12-12 | 2002-03-28 | Warner Lambert Co | Statin-carboxyalkylether combinations useful for treating vascular disorders and diabetes mellitus |
| GB9903472D0 (en) * | 1999-02-17 | 1999-04-07 | Zeneca Ltd | Chemical process |
| EP1161236A1 (en) * | 1999-03-08 | 2001-12-12 | Merck & Co., Inc. | Dihydroxy open-acid and salts of hmg-co-a reductase inhibitors |
| NZ526022A (en) * | 2000-11-16 | 2005-04-29 | Teva Pharma | Hydrolysis of [R(R*,R )]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid esters with calcium hydroxide |
| IL156055A0 (en) * | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
| AU2007205725A1 (en) * | 2000-11-30 | 2007-08-30 | Teva Pharmaceutical Industries Ltd. | Novel cyrstal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
| PL365312A1 (en) * | 2000-12-27 | 2004-12-27 | Teva Pharmaceutical Industries Ltd | Crystalline forms of atorvastatin |
| CA2456095C (en) * | 2001-08-31 | 2010-05-11 | Morepen Laboratories Ltd. | An improved process for the preparation of amorphous atorvastatin calcium salt (2:1) |
-
2002
- 2002-08-16 SK SK140-2004A patent/SK1402004A3/sk not_active Application Discontinuation
- 2002-08-16 WO PCT/US2002/026012 patent/WO2003016317A1/en active IP Right Grant
- 2002-08-16 HU HU0500616A patent/HUP0500616A3/hu unknown
- 2002-08-16 NZ NZ529913A patent/NZ529913A/en unknown
- 2002-08-16 EP EP02759374A patent/EP1425287A4/en not_active Withdrawn
- 2002-08-16 PL PL02370407A patent/PL370407A1/xx unknown
- 2002-08-16 IL IL16007702A patent/IL160077A0/xx active IP Right Grant
- 2002-08-16 CZ CZ2004337A patent/CZ2004337A3/cs unknown
- 2002-08-16 AU AU2002324715A patent/AU2002324715B2/en not_active Expired - Fee Related
- 2002-08-16 JP JP2003521239A patent/JP4188826B2/ja not_active Expired - Lifetime
- 2002-08-16 TR TR2003/02281T patent/TR200302281T2/xx unknown
- 2002-08-16 CA CA2450820A patent/CA2450820C/en not_active Expired - Fee Related
- 2002-08-16 MX MXPA04001451A patent/MXPA04001451A/es not_active Application Discontinuation
- 2002-08-16 CN CNB028159993A patent/CN100430405C/zh not_active Expired - Fee Related
-
2004
- 2004-01-27 IL IL160077A patent/IL160077A/en not_active IP Right Cessation
- 2004-02-11 IS IS7148A patent/IS7148A/is unknown
- 2004-03-15 NO NO20041082A patent/NO20041082L/no not_active Application Discontinuation
- 2004-03-15 HR HR20040255A patent/HRPK20040255B3/xx not_active IP Right Cessation
-
2008
- 2008-07-15 JP JP2008184147A patent/JP2009024008A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| HRP20040255A2 (en) | 2004-08-31 |
| SK1402004A3 (sk) | 2005-01-03 |
| JP4188826B2 (ja) | 2008-12-03 |
| IL160077A (en) | 2007-10-31 |
| PL370407A1 (en) | 2005-05-30 |
| IS7148A (is) | 2004-02-11 |
| TR200302281T2 (tr) | 2004-09-21 |
| WO2003016317A1 (en) | 2003-02-27 |
| IL160077A0 (en) | 2004-06-20 |
| CN1543468A (zh) | 2004-11-03 |
| EP1425287A1 (en) | 2004-06-09 |
| CA2450820A1 (en) | 2003-02-27 |
| CN100430405C (zh) | 2008-11-05 |
| AU2002324715B2 (en) | 2009-03-12 |
| HRPK20040255B3 (en) | 2006-02-28 |
| HUP0500616A2 (hu) | 2005-11-28 |
| MXPA04001451A (es) | 2005-02-17 |
| NZ529913A (en) | 2005-03-24 |
| JP2009024008A (ja) | 2009-02-05 |
| NO20041082L (no) | 2004-03-15 |
| JP2005500382A (ja) | 2005-01-06 |
| CZ2004337A3 (cs) | 2005-01-12 |
| CA2450820C (en) | 2011-03-15 |
| EP1425287A4 (en) | 2005-09-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL160077A0 (en) | Processes for preparing calcium salt forms of statins | |
| IL166626A0 (en) | Process for preparing the calcium salt of rosuvastatin | |
| IL173858A0 (en) | Process for preparation of rosuvastatin calcium | |
| HUP0302755A3 (en) | Method of synthesizing camptothecin-relating compounds | |
| HK1087405A1 (en) | Improved production of the rosuvastatin calcium salt | |
| SI1390023T1 (sl) | Farmacevtske soli spojin 1-fenil-3-dimetilamino-propana | |
| AP2002002550A0 (en) | Chiral salt resolution | |
| NZ523557A (en) | Calcium salt of valsartan | |
| IL165584A0 (en) | Novel formate salt of o-desmethyl-venlafaxine | |
| IL159626A0 (en) | Crystalline forms of atorvastatin calcium and processes for the preparation thereof | |
| PL367278A1 (en) | Method for inhibiting calcium salt scale | |
| EP1572638A4 (en) | IMPROVED PROCESS FOR THE PREPARATION OF AMORPHOUS CALCIUM ATORVASTATIN SALT (2: 1) | |
| PL367302A1 (en) | Method for inhibiting calcium salt scale | |
| IL143106A (en) | Process for the preparation of diphenylmethylthioacetamide | |
| PL355958A1 (en) | Application of statins for inhibiting formation of osteoclasts | |
| HUP0500644A3 (en) | Method of synthesizing phenol-containing compounds | |
| IL159355A0 (en) | Process for the preparation of nitrile compounds | |
| IL161386A0 (en) | Bone anti-resorptive compounds | |
| SG108831A1 (en) | Process for preventing formation of scale | |
| HUP0303025A3 (en) | Process for the preparation of arylethanoldiamines | |
| HUP0303123A3 (en) | Method of purifying pravastatin or its pharmacologically acceptable salt | |
| PL368905A1 (en) | Process for the preparation of beta-ionylideneacetaldehyde | |
| AU2002329110A1 (en) | Method for preparing calcium gluconate | |
| SI1395580T1 (en) | Method for the purification of triazolylmethylepoxides | |
| HU0100184V0 (en) | Method for forming of smokingset |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA9A | Lapse of provisional patent protection due to relinquishment or protection considered relinquished |